Genedrive PLC's (LON:GDR) David Budd recaps on its two coronavirus test kits. The first, which was CE marked last week and they're in the process of launching, is a high-throughput lab-based PCR test which assesses whether someone's got an active infection. The second is a point-of-care version of the test which can be done outside of hospitals. Budd also discusses WHO approval received for its HCV test as well as new distribution arrangements for its infant deafness test.
Genedrive's David Budd details launch of its unique coronavirus test kits and plans for first sales
Quick facts: Genedrive PLC
Price: 40.5 GBX
Market Cap: £25.59 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Genedrive PLC named herein, including the promotion by the Company of Genedrive PLC in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE